


Recs developed for neoadjuvant chemo in ovarian cancer

August 9 2016



(HealthDay)—Guidelines have been developed for neoadjuvant

chemotherapy use for newly diagnosed, advanced ovarian cancer. The clinical practice guideline was published online Aug. 8 in the *Journal of Clinical Oncology*.

Alexi A. Wright, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues offer guidance to clinicians regarding the use of neoadjuvant [chemotherapy](#) and interval cytoreduction in women with stage IIIC or IV epithelial ovarian cancer. The primary evidence base for recommendations was four phase III clinical trials.

The authors note that all women with suspected stage IIIC or IV invasive [epithelial ovarian cancer](#) should undergo gynecologic oncologist assessment before initiation of treatment. The primary [clinical](#) evaluation should include abdomen and pelvis computed tomography (CT) and chest imaging (ideally CT). Neoadjuvant chemotherapy is recommended for women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to

Citation: Recs developed for neoadjuvant chemo in ovarian cancer (2016, August 9) retrieved 5 April 2023 from <https://medicalxpress.com/news/2016-08-recs-neoadjuvant-chemo-ovarian-cancer.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--